{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:15:05Z","timestamp":1761110105854,"version":"3.40.4"},"reference-count":171,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.eimc.2014.02.020","type":"journal-article","created":{"date-parts":[[2014,6,7]],"date-time":"2014-06-07T11:15:40Z","timestamp":1402139740000},"page":"e15-e30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Interacciones graves o potencialmente letales entre antirretrovirales y otros medicamentos"],"prefix":"10.1016","volume":"33","author":[{"given":"Christian","family":"Manzardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Tuset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2014.02.020_bib0005","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.020_bib0010","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-138-8-200304150-00007","article-title":"Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata","volume":"138","author":"Palella","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2014.02.020_bib0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.NAJ.0000368952.80634.42","article-title":"Aging with HIV: Clinical considerations for an emerging population","volume":"110","author":"Vance","year":"2010","journal-title":"Am J Nurs"},{"key":"10.1016\/j.eimc.2014.02.020_bib0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/CIA.S14726","article-title":"Successful aging and the epidemiology of HIV","volume":"6","author":"Vance","year":"2011","journal-title":"Clin Interv Aging"},{"issue":"Suppl 1","key":"10.1016\/j.eimc.2014.02.020_bib0025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jis927","article-title":"An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection","volume":"207","author":"Kim","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0030","first-page":"82","article-title":"The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: Diagnostic, assessment, and treatment principles","volume":"24","author":"Ramasubbu","year":"2012","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.eimc.2014.02.020_bib0035","doi-asserted-by":"crossref","DOI":"10.1089\/aid.2012.0321","article-title":"Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era","author":"Albini","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2014.02.020_bib0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/hiv.12034","article-title":"Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy, 1999-2009","volume":"14","author":"Calabresi","year":"2013","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.020_bib0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11904-013-0166-8","article-title":"Non-AIDS-defining cancers among HIV-infected patients","volume":"10","author":"Cutrell","year":"2013","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.eimc.2014.02.020_bib0050","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/cid\/cit369","article-title":"Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy","volume":"57","author":"Yanik","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0055","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.recesp.2010.12.007","article-title":"Heart transplantation in an HIV-1-infected patient with ischemic cardiomyopathy and severe pulmonary hypertension","volume":"64","author":"Castel","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0060","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1600-6143.2012.04028.x","article-title":"Outcome of HCV\/HIV-coinfected liver transplant recipients: A prospective and multicenter cohort study","volume":"12","author":"Miro","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2014.02.020_bib0065","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/ki.2010.545","article-title":"Renal transplantation in HIV-infected patients: 2010 update","volume":"79","author":"Trullas","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.eimc.2014.02.020_bib0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11908-011-0229-1","article-title":"Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: An update on new interactions between HIV and non-HIV drugs","volume":"14","author":"Tseng","year":"2012","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.eimc.2014.02.020_bib0075","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1086\/652149","article-title":"Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy","volume":"50","author":"Evans-Jones","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0080","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3851\/IMP1540","article-title":"Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study","volume":"15","author":"Marzolini","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0085","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/jac\/dkr248","article-title":"Ageing with HIV: Medication use and risk for potential drug-drug interactions","volume":"66","author":"Marzolini","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2014.02.020_bib0090","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1592\/phco.31.5.480","article-title":"Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy","volume":"31","author":"Yiu","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eimc.2014.02.020_bib0095","first-page":"1179","article-title":"Molecular basis of P450 inhibition and activation: Implications for drug development and drug therapy","volume":"26","author":"Szklarz","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.eimc.2014.02.020_bib0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0105","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1023\/A:1018877803319","article-title":"Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein","volume":"16","author":"Kim","year":"1999","journal-title":"Pharm Res"},{"key":"10.1016\/j.eimc.2014.02.020_bib0110","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1470-2045(11)70056-0","article-title":"Use of antineoplastic agents in patients with cancer who have HIV\/AIDS","volume":"12","author":"Rudek","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0115","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/0091270010375959","article-title":"Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: In vitro\/in vivo correlation","volume":"51","author":"Brainard","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0091270007310382","article-title":"Lack of a pharmacokinetic effect of raltegravir on midazolam: In vitro\/in vivo correlation","volume":"48","author":"Iwamoto","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0125","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1124\/dmd.107.016196","article-title":"Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme","volume":"35","author":"Kassahun","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.eimc.2014.02.020_bib0130","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1345\/aph.1R468","article-title":"Elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment","volume":"46","author":"Olin","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimc.2014.02.020_bib0135","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.eimc.2014.02.020_bib0140","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0145","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1526-4610.2003.03034.x","article-title":"Ergotamine and dihydroergotamine: History, pharmacology, and efficacy","volume":"43","author":"Silberstein","year":"2003","journal-title":"Headache"},{"key":"10.1016\/j.eimc.2014.02.020_bib0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1468-2982.1983.0301015.x","article-title":"Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study","volume":"3","author":"Ekbom","year":"1983","journal-title":"Cephalalgia"},{"key":"10.1016\/j.eimc.2014.02.020_bib0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1468-2982.1981.0104203.x","article-title":"Low biological availability of ergotamine tartrate after oral dosing in cluster headache","volume":"1","author":"Ekbom","year":"1981","journal-title":"Cephalalgia"},{"key":"10.1016\/j.eimc.2014.02.020_bib0160","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1046\/j.1526-4610.2002.02163.x","article-title":"Fatal ergotism induced by an HIV protease inhibitor","volume":"42","author":"Tribble","year":"2002","journal-title":"Headache"},{"key":"10.1016\/j.eimc.2014.02.020_bib0165","unstructured":"Efavirenz (Sustiva\u00ae). Ficha t\u00e9cnica. Laboratorios Bristol-Myers Squibb Pharma, Uxbridge, Reino Unido. Noviembre 2012 [consultado 29 Sep 2013]. Disponible en: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/humanmedicines000249human_med_001068.jsp&mid=WC0b01ac058001d124"},{"key":"10.1016\/j.eimc.2014.02.020_bib0170","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/0003-4819-109-8-682","article-title":"Lovastatin and rhabdomyolysis","volume":"109","author":"Ayanian","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2014.02.020_bib0175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/00498250903509375","article-title":"Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1","volume":"40","author":"Annaert","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1016\/j.eimc.2014.02.020_bib0180","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0185","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1086\/344179","article-title":"Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death","volume":"35","author":"Hare","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0190","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3122\/jabfm.2007.04.060187","article-title":"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir","volume":"20","author":"Schmidt","year":"2007","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.eimc.2014.02.020_bib0195","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1128\/AAC.00449-09","article-title":"Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers","volume":"53","author":"Pham","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2014.02.020_bib0200","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FJC.0b013e31817b5b5a","article-title":"Effects of atazanavir\/ritonavir or fosamprenavir\/ritonavir on the pharmacokinetics of rosuvastatin","volume":"51","author":"Busti","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0205","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3851\/IMP1747","article-title":"Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir\/ritonavir","volume":"16","author":"De Kanter","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0210","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","article-title":"Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors","volume":"52","author":"Chauvin","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0215","first-page":"144","article-title":"Combined use of astemizole and ketoconazole resulting in torsade de pointes","volume":"96","author":"Tsai","year":"1997","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.eimc.2014.02.020_bib0220","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1001\/jama.1990.03450210088038","article-title":"Torsades de pointes occurring in association with terfenadine use","volume":"264","author":"Monahan","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2014.02.020_bib0225","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0014-5793(97)01249-0","article-title":"A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG","volume":"417","author":"Rampe","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.eimc.2014.02.020_bib0230","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0009-9236(99)70117-7","article-title":"Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)","volume":"65","author":"Desta","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0235","first-page":"292","article-title":"Pharmacokinetic overview of oral second-generation H1 antihistamines","volume":"36","author":"Gonzalez","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0240","unstructured":"European Medicines Agency recommends changes to the use of metoclopramide EMA\/443003\/2013\/rev.1 September 2013 [consultado 29 Sep 2013]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB document_library\/Referrals_document\/Metoclopramide_31\/WC500146610.pdf"},{"key":"10.1016\/j.eimc.2014.02.020_bib0245","unstructured":"Domperidona y riesgo card\u00edaco. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitario. MUH (FV), 24\/2011. Diciembre 2011 [consultado 29 Sep 2013]. Disponible en: http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2011\/NI-MUH_24-2011.htm"},{"key":"10.1016\/j.eimc.2014.02.020_bib0250","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/01.aids.0000174445.40379.e0","article-title":"The potential for interactions between antimalarial and antiretroviral drugs","volume":"19","author":"Khoo","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0255","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.2009.03566.x","article-title":"Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration","volume":"69","author":"Soyinka","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0260","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10096-007-0293-5","article-title":"Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir","volume":"26","author":"L\u00fcthi","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0265","doi-asserted-by":"crossref","first-page":"524764","DOI":"10.4061\/2010\/524764","article-title":"Torsade de pointes due to methadone use in a patient with HIV and hepatitis C coinfection","volume":"2010","author":"John","year":"2010","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.eimc.2014.02.020_bib0270","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1345\/aph.1Q422","article-title":"Protease inhibitor-associated QT interval prolongation","volume":"45","author":"Hunt","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimc.2014.02.020_bib0275","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0009-9236(99)70051-2","article-title":"Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam","volume":"66","author":"Palkama","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0280","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2174\/138955710791572451","article-title":"Drug interactions during periodontal therapy in HIV-infected subjects","volume":"10","author":"Goncalves","year":"2010","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.eimc.2014.02.020_bib0285","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1067\/mcp.2000.105757","article-title":"Alprazolam-ritonavir interaction: Implications for product labeling","volume":"67","author":"Greenblatt","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0290","first-page":"84","article-title":"Study of interactions between anti-retroviral agents and concomitant drugs","volume":"27","author":"Mur Lalaguna","year":"2003","journal-title":"Farm Hosp"},{"key":"10.1016\/j.eimc.2014.02.020_bib0295","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/00023210-200317070-00004","article-title":"Clinically important drug interactions with zopiclone, zolpidem and zaleplon","volume":"17","author":"Hesse","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eimc.2014.02.020_bib0300","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1345\/aph.1C146","article-title":"Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction","volume":"37","author":"Clay","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimc.2014.02.020_bib0305","unstructured":"Gastaldo JM, Nedig JL, Para MF, Diaz PT. The Clinical Significance of the Drug Interaction between Protease Inhibitors and Midazolam [abstract n.\u00b0 422]. En 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canad\u00e1; 2000."},{"key":"10.1016\/j.eimc.2014.02.020_bib0310","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/j.1875-9114.2011.01045.x","article-title":"Severe prolonged sedation associated with coadministration of protease inhibitors and intravenous midazolam during bronchoscopy","volume":"32","author":"Hsu","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eimc.2014.02.020_bib0315","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1592\/phco.29.11.1386","article-title":"Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients","volume":"29","author":"Pollack","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eimc.2014.02.020_bib0320","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/187231210790980426","article-title":"Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose","volume":"4","author":"Hantson","year":"2010","journal-title":"Drug Metab Lett"},{"key":"10.1016\/j.eimc.2014.02.020_bib0325","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12245-010-0175-y","article-title":"Antipsychotic-induced priapism in an HIV patient: A cytochrome P450-mediated drug interaction","volume":"3","author":"Geraci","year":"2010","journal-title":"Int J Emerg Med"},{"key":"10.1016\/j.eimc.2014.02.020_bib0330","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1345\/aph.1G630","article-title":"Carbamazepine toxicity induced by lopinavir\/ritonavir and nelfinavir","volume":"40","author":"Bates","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimc.2014.02.020_bib0335","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1528-1167.2011.03335.x","article-title":"Antiepileptic drug selection for people with HIV\/AIDS: Evidence-based guidelines from the ILAE and AAN","volume":"53","author":"Birbeck","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.eimc.2014.02.020_bib0340","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1592\/phco.22.15.1312.33478","article-title":"Symptomatic orthostasis with extended-release nifedipine and protease inhibitors","volume":"22","author":"Rossi","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eimc.2014.02.020_bib0345","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0140-6736(99)90041-7","article-title":"Possible interaction between sildenafil and HIV combination therapy","volume":"353","author":"Nandwani","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0350","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0140-6736(05)77889-2","article-title":"Interaction between sildenafil and HIV-1 combination therapy","volume":"353","author":"Hall","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0355","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/157016212799937263","article-title":"Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors","volume":"10","author":"Chinello","year":"2012","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.eimc.2014.02.020_bib0360","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/11534740-000000000-00000","article-title":"Pharmacokinetic interactions between etravirine and non-antiretroviral drugs","volume":"50","author":"Kakuda","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0365","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MAJ.0b013e31824ceb2b","article-title":"Ritonavir and epidural triamcinolone as a cause of iatrogenic Cushing's syndrome","volume":"344","author":"Albert","year":"2012","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.eimc.2014.02.020_bib0370","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-0031-1297993","article-title":"Hypercortisolism caused by ritonavir associated inhibition of CYP3A4 under inhalative glucocorticoid therapy. 2 case reports and a review of the literature","volume":"120","author":"Bernecker","year":"2012","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.eimc.2014.02.020_bib0375","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1503\/cmaj.111315","article-title":"Cushing syndrome due to ritonavir-fluticasone interaction","volume":"184","author":"Canalejo","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.eimc.2014.02.020_bib0380","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1345\/aph.1P731","article-title":"Cushing's syndrome due to antiretroviral-budesonide interaction","volume":"45","author":"Frankel","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimc.2014.02.020_bib0385","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/02770903.2010.485666","article-title":"Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient","volume":"47","author":"Kedem","year":"2010","journal-title":"J Asthma"},{"key":"10.1016\/j.eimc.2014.02.020_bib0390","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaad.2010.09.014","article-title":"Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy","volume":"65","author":"Levine","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0395","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/QAD.0b013e328347c09c","article-title":"Cushing's syndrome and adrenal axis suppression in a patient treated with ritonavir and corticosteroid eye drops","volume":"25","author":"Molloy","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0400","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s15010-013-0506-z","article-title":"Triamcinolone and ritonavir leading to drug-induced Cushing syndrome and adrenal suppression: description of a new case and review of the literature","volume":"41","author":"Schwarze-Zander","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.eimc.2014.02.020_bib0405","article-title":"Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: A case report and review","author":"Song","year":"2013","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.eimc.2014.02.020_bib0410","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1258\/ijsa.2011.011408","article-title":"Cushing's syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infection","volume":"23","author":"Yoganathan","year":"2012","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0415","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1468-1293.2008.00579.x","article-title":"Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: A review of the literature","volume":"9","author":"Foisy","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.02.020_bib0420","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/17425255.2013.772579","article-title":"Drug interactions between antiretrovirals and hormonal contraceptives","volume":"9","author":"Tseng","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0425","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350801300415","article-title":"Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women","volume":"13","author":"Sekar","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0430","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/QAI.0b013e31827e8f98","article-title":"Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives","volume":"62","author":"Landolt","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.020_bib0435","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.contraception.2009.01.009","article-title":"Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone","volume":"80","author":"Scholler-Gyure","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.eimc.2014.02.020_bib0440","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11531240-000000000-00000","article-title":"Drug interactions with new and investigational antiretrovirals","volume":"49","author":"Crauwels","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1016\/j.eimc.2014.02.020_bib0445","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2125.2008.03132.x","article-title":"Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine\/zidovudine, and ethinyloestradiol\/levonorgestrel in healthy volunteers","volume":"65","author":"Abel","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0450","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1365-2125.2010.03885.x","article-title":"Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women","volume":"71","author":"Anderson","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0455","unstructured":"Faculty of Sexual & Reproductive Healthcare Clinical Guidance. Drug Interactions with Hormonal Contraception Clinical Effectiveness Unit. January 2011 (Updated January 2012). Drug Interactions with Hormonal Contraception Clinical Effectiveness Unit January 2011 (Updated January 2012). UK [consultado 7 Sep 2013]. Disponible en: http:\/\/www.fsrh.org\/pdfs\/CEUguidancedruginteractionshormonal.pdf"},{"key":"10.1016\/j.eimc.2014.02.020_bib0460","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2007.11.009","article-title":"Viral hepatitis and HIV coinfection","volume":"48","author":"Sulkowski","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0465","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/QAD.0b013e3283454174","article-title":"The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients","volume":"25","author":"Lopez-Dieguez","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0470","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","article-title":"Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis","volume":"22","author":"Thein","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0475","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2893.2006.00824.x","article-title":"Response rates to pegylated interferon and ribavirin in HCV\/HIV coinfection: A research synthesis","volume":"14","author":"Shire","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.eimc.2014.02.020_bib0480","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJMc1105515","article-title":"Boceprevir for chronic HCV genotype 1 infection","volume":"365","author":"Limaye","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.020_bib0485","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.02.020_bib0490","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","article-title":"Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: A randomized trial","volume":"159","author":"Sulkowski","year":"2013","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.eimc.2014.02.020_bib0495","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1093\/infdis\/jis764","article-title":"Current management of hepatitis C virus infection in patients with HIV co-infection","volume":"207","author":"Sulkowski","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0500","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","article-title":"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial","volume":"13","author":"Sulkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0505","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2125.2012.04345.x","article-title":"The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers","volume":"75","author":"Garg","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0510","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3851\/IMP2356","article-title":"Telaprevir: pharmacokinetics and drug interactions","volume":"17","author":"Garg","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0515","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1124\/dmd.112.049668","article-title":"In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters","volume":"41","author":"Chu","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.eimc.2014.02.020_bib0520","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1177\/0091270011419850","article-title":"Effect of telaprevir on the pharmacokinetics of midazolam and digoxin","volume":"52","author":"Garg","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0525","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/QAI.0b013e318275da93","article-title":"Pharmacokinetic interaction between boceprevir and etravirine in HIV\/HCV seronegative volunteers","volume":"62","author":"Hammond","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2014.02.020_bib0530","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/cid\/cis968","article-title":"Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir","volume":"56","author":"Hulskotte","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0535","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/cid\/cis824","article-title":"Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir","volume":"56","author":"de Kanter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0540","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3851\/IMP2527","article-title":"Review of drug interactions with telaprevir and antiretrovirals","volume":"18","author":"Van Heeswijk","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0545","unstructured":"Berenguer J, Calleja JL, Esteban R, Fern\u00e1ndez MJ, Forns X, J G. Agencia Espa\u00f1ola del Medicamento. Recomendaciones de uso de medicamentos en condiciones distintas a las autorizadas. Criterios y recomendaciones generales para el tratamiento con boceprevir y telaprevir de la hepatitis cr\u00f3nica C en pacientes infectados por el VIH, en trasplantados de h\u00edgado y en poblaci\u00f3n pedi\u00e1tric [consultado 24 Jul 2013]. Disponible en: http:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/medSituacionesEspeciales\/docs\/criterios-VHC-off-label.pdf"},{"key":"10.1016\/j.eimc.2014.02.020_bib0550","series-title":"20th Conference on Retroviruses and Opportunistic Infections","article-title":"Absence of a significant pharmacokinetic interaction between the hepatitis C Virus protease inhibitor boceprevir and HIV-1 NNRTI rilpivirine","author":"Rhee","year":"2013"},{"key":"10.1016\/j.eimc.2014.02.020_bib0555","unstructured":"Stribild\u00ae (elvitegravir, cobicistat, emtricitabina, tenofovir fumarato). Ficha t\u00e9cnica [consultado 21 Oct 2013]. Disponible en: http:\/\/ec.europa.eu\/health\/documents\/community-register\/2013\/20130524125854\/anx_125854_es.pdf"},{"key":"10.1016\/j.eimc.2014.02.020_bib0560","series-title":"14th International Workshop on Clinical Pharmacology of HIV Therapy 22-24 April","article-title":"The effect of boceprevir and telaprevir on dolutegravir pharmacokinetics, in healthy adult subjects [abstract O-16]","author":"Johnson","year":"2013"},{"key":"10.1016\/j.eimc.2014.02.020_bib0565","series-title":"14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24","article-title":"The effect of boceprevir and telaprevir on the pharmacokinetics of maraviroc: An open-label, fixed-sequence study in healthy volunteers [abstract O-17]","author":"Vourvahis","year":"2013"},{"key":"10.1016\/j.eimc.2014.02.020_bib0570","unstructured":"Victrelis\u00ae (Boceprevir). Ficha t\u00e9cnica [consultado 21 Oct 2013]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/002332\/WC500109786.pdf"},{"key":"10.1016\/j.eimc.2014.02.020_bib0575","unstructured":"Incivo\u00ae (Telaprevir). Ficha t\u00e9cnica [consultado 21 Oct 2013]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/002313\/WC500115529.pdf"},{"key":"10.1016\/j.eimc.2014.02.020_bib0580","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/rmv.620","article-title":"Solid organ transplantation in HIV-infected individuals: An update","volume":"19","author":"Huprikar","year":"2009","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0585","first-page":"16","article-title":"Solid organ transplantation and HIV infection","volume":"8","author":"Polak","year":"2003","journal-title":"Ann Transplant"},{"key":"10.1016\/j.eimc.2014.02.020_bib0590","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF02696657","article-title":"Solid organ transplantation is a reality for patients with HIV infection","volume":"3","author":"Roland","year":"2006","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.eimc.2014.02.020_bib0595","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.healun.2011.07.022","article-title":"Heart transplantation in HIV-infected patients: More cases in Europe","volume":"30","author":"Castel","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.eimc.2014.02.020_bib0600","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/apc.2012.0169","article-title":"Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: A review","volume":"26","author":"Van Maarseveen","year":"2012","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0605","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1016\/j.transproceed.2010.09.003","article-title":"Simultaneous pancreas-kidney transplantation in HIV-infected patients: A case report and literature review","volume":"42","author":"Miro","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.eimc.2014.02.020_bib0610","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/lt.22005","article-title":"Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation","volume":"16","author":"Moreno","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.eimc.2014.02.020_bib0615","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1600-6143.2009.02684.x","article-title":"Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs","volume":"9","author":"Tricot","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2014.02.020_bib0620","series-title":"18th Conference on Retrovirus and Opportunistic Infections","article-title":"Combination of raltegravir plus lamivudine or emtricitabine plus abacavir or tenofovir is safe, effective and prevents pharmacokinetic interactions with immunosuppressive drugs in HIV-infected solid organ transplant recipients","author":"Miro","year":"2011"},{"key":"10.1016\/j.eimc.2014.02.020_bib0625","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/QAD.0b013e32802ef30c","article-title":"Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy","volume":"21","author":"Lima","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0630","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/cid\/cis613","article-title":"The rising challenge of non-AIDS-defining cancers in HIV-infected patients","volume":"55","author":"Deeken","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0635","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1097\/QAD.0b013e328314b5f1","article-title":"Patients presenting with AIDS in the HAART era: A collaborative cohort analysis","volume":"22","author":"Mussini","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0640","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1086\/656416","article-title":"Cancer as a cause of death among people with AIDS in the United States","volume":"51","author":"Simard","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0645","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.25547","article-title":"Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States","volume":"117","author":"Simard","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eimc.2014.02.020_bib0650","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/QAD.0b013e328353f38e","article-title":"Mortality due to cancer among people with AIDS: A novel approach using registry-linkage data and population attributable risk methods","volume":"26","author":"Simard","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0655","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1158\/1055-9965.EPI-11-0823","article-title":"Long-term cancer risk among people diagnosed with AIDS during childhood","volume":"21","author":"Simard","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.eimc.2014.02.020_bib0660","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1002\/cncr.28252","article-title":"Trends in the occurrence of high-grade anal intraepithelial neoplasia in San Francisco: 2000-2009","volume":"119","author":"Simard","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.eimc.2014.02.020_bib0665","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ajh.21947","article-title":"Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: A multicenter study","volume":"86","author":"Castillo","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0670","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1040-8428(01)00165-2","article-title":"AIDS-related tumors: Integrating antiviral and anticancer therapy","volume":"41","author":"Tirelli","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0675","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1086\/379517","article-title":"Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy","volume":"37","author":"Vaccher","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0680","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/JTO.0b013e318217b6e0","article-title":"Human immunodeficiency virus infection and non-small cell lung cancer: Survival and toxicity of antineoplastic chemotherapy in a cohort study","volume":"6","author":"Makinson","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0685","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1086\/511875","article-title":"Prolonged QT interval and torsades de pointes associated with atazanavir therapy","volume":"44","author":"Ly","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.02.020_bib0690","first-page":"104","article-title":"Atazanavir: new indication. First-line treatment: Fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de, pointes","volume":"18","year":"2009","journal-title":"Prescrire Int"},{"key":"10.1016\/j.eimc.2014.02.020_bib0695","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(05)70936-3","article-title":"Blockade of HERG channels by HIV protease inhibitors","volume":"365","author":"Anson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0700","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0091270011400071","article-title":"Thorough QT\/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants","volume":"52","author":"Zhang","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0705","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pharmthera.2009.10.002","article-title":"Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy","volume":"125","author":"Raschi","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0710","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-07-0346","article-title":"Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib","volume":"13","author":"Van Erp","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eimc.2014.02.020_bib0715","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2435.x","article-title":"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease","volume":"76","author":"Kotb","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0720","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11096-009-9323-y","article-title":"Paralytic ileus possibly associated with interaction between ritonavir\/lopinavir and vincristine","volume":"31","author":"Leveque","year":"2009","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.eimc.2014.02.020_bib0725","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/QAD.0b013e328300ca98","article-title":"Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma","volume":"22","author":"Loulergue","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0730","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2125.2009.03555.x","article-title":"Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients","volume":"69","author":"Mir","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0735","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.coc.0000045921.91037.C8","article-title":"Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma","volume":"27","author":"Bundow","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0740","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00001622-199709050-00010","article-title":"The use of new antiretroviral therapy in combination with chemotherapy","volume":"9","author":"Tan","year":"1997","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0745","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2001.19.8.2171","article-title":"Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy","volume":"19","author":"Ratner","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0750","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1097\/QAD.0b013e32833d1243","article-title":"Deleterious pharmacokinetic interaction between bexarotene and efavirenz","volume":"24","author":"Desnoyer","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0755","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1345\/aph.1M370","article-title":"Raltegravir-based HAART regimen in a patient with large B-cell lymphoma","volume":"44","author":"Fulco","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimc.2014.02.020_bib0760","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1176\/appi.psy.46.1.79","article-title":"Med-psych drug-drug interactions update. Antiretrovirals, part III: Antiretrovirals and drugs of abuse","volume":"46","author":"Wynn","year":"2005","journal-title":"Psychosomatics"},{"key":"10.1016\/j.eimc.2014.02.020_bib0765","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.lfs.2010.09.012","article-title":"Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals","volume":"88","author":"Pal","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.eimc.2014.02.020_bib0770","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/archinte.159.18.2221","article-title":"Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate","volume":"159","author":"Harrington","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2014.02.020_bib0775","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(05)75654-3","article-title":"Fatal MDMA intoxication","volume":"353","author":"Schwab","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0780","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(05)75653-1","article-title":"Fatal MDMA intoxication","volume":"353","author":"De la Torre","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0785","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(05)79824-X","article-title":"Fatal interaction between ritonavir and MDMA","volume":"352","author":"Henry","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0790","first-page":"651","article-title":"Transient haemolytic anaemia due to ecstasy in a patient on HAART","volume":"13","author":"Goorney","year":"2002","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0795","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00134-012-2537-9","article-title":"Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV)","volume":"38","author":"Papaseit","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.eimc.2014.02.020_bib0800","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11584550-000000000-00000","article-title":"Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans","volume":"50","author":"Yubero-Lahoz","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0805","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fgene.2012.00235","article-title":"MDMA, methamphetamine, and CYP2D6 pharmacogenetics: What is clinically relevant?","volume":"3","author":"De la Torre","year":"2012","journal-title":"Front Genet"},{"key":"10.1016\/j.eimc.2014.02.020_bib0810","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000139058","article-title":"Norcocaine and N-hydroxynorcocaine formation in human liver microsomes: Role of cytochrome P-450 3A4","volume":"46","author":"LeDuc","year":"1993","journal-title":"Pharmacology"},{"key":"10.1016\/j.eimc.2014.02.020_bib0815","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.286.3.295-JHA10006-4-1","article-title":"Health agencies update. HIV and heroin interactions","volume":"286","author":"Vastag","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2014.02.020_bib0820","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2125.1993.tb05666.x","article-title":"Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone","volume":"35","author":"Wu","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0825","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/00002030-199905280-00012","article-title":"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone","volume":"13","author":"Altice","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0830","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/00002030-199905280-00025","article-title":"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: An alert","volume":"13","author":"Otero","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.02.020_bib0835","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/clpt.2011.276","article-title":"Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics","volume":"91","author":"Kharasch","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimc.2014.02.020_bib0840","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/088922202753519115","article-title":"Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment","volume":"18","author":"Boffito","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2014.02.020_bib0845","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0091270007310387","article-title":"Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers","volume":"48","author":"Scholler-Gyure","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eimc.2014.02.020_bib0850","first-page":"87","article-title":"Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine","volume":"15","author":"Crauwels","year":"2013","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2014.02.020_bib0855","first-page":"2510","article-title":"Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors","volume":"12","author":"Beauverie","year":"1998","journal-title":"AIDS"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14001244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14001244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T07:50:38Z","timestamp":1746258638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X14001244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":171,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0213005X14001244"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2014.02.020","relation":{},"ISSN":["0213-005X"],"issn-type":[{"type":"print","value":"0213-005X"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interacciones graves o potencialmente letales entre antirretrovirales y otros medicamentos","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2014.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}